These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 1356418

  • 1. Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice.
    Kuo MT, Zhao JY, Teeter LD, Ikeguchi M, Chisari FV.
    Cell Growth Differ; 1992 Aug; 3(8):531-40. PubMed ID: 1356418
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tissue distribution of the human MDR3 P-glycoprotein.
    Smit JJ, Schinkel AH, Mol CA, Majoor D, Mooi WJ, Jongsma AP, Lincke CR, Borst P.
    Lab Invest; 1994 Nov; 71(5):638-49. PubMed ID: 7734012
    [Abstract] [Full Text] [Related]

  • 5. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
    Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS.
    Oncogene; 2000 Oct 19; 19(44):5054-62. PubMed ID: 11042693
    [Abstract] [Full Text] [Related]

  • 6. Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma.
    Pousset D, Piller V, Bureaud N, Monsigny M, Piller F.
    Cancer Res; 1997 Oct 01; 57(19):4249-56. PubMed ID: 9331085
    [Abstract] [Full Text] [Related]

  • 7. Genes amplified and overexpressed in human multidrug-resistant cell lines.
    Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H, Borst P.
    Cancer Res; 1988 Nov 01; 48(21):5927-32. PubMed ID: 2901906
    [Abstract] [Full Text] [Related]

  • 8. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.
    Huang SN, Chisari FV.
    Hepatology; 1995 Mar 01; 21(3):620-6. PubMed ID: 7875658
    [Abstract] [Full Text] [Related]

  • 9. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells.
    Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT.
    Endocrinology; 1993 Aug 01; 133(2):521-8. PubMed ID: 8102093
    [Abstract] [Full Text] [Related]

  • 10. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis.
    Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, Kuo MT.
    Mol Carcinog; 1993 Aug 01; 8(2):67-73. PubMed ID: 8104413
    [Abstract] [Full Text] [Related]

  • 11. Structural and functional characterization of the mouse multidrug resistance gene family.
    Dhir R, Buschman E, Gros P.
    Bull Cancer; 1990 Aug 01; 77(11):1125-9. PubMed ID: 1980424
    [Abstract] [Full Text] [Related]

  • 12. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene.
    Sepulveda AR, Finegold MJ, Smith B, Slagle BL, DeMayo JL, Shen RF, Woo SL, Butel JS.
    Cancer Res; 1989 Nov 01; 49(21):6108-17. PubMed ID: 2551499
    [Abstract] [Full Text] [Related]

  • 13. Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas.
    Kimura O, Yamaguchi Y, Gunning KB, Teeter LD, Husain F, Kuo MT.
    Hum Gene Ther; 1994 Jul 01; 5(7):845-52. PubMed ID: 7981309
    [Abstract] [Full Text] [Related]

  • 14. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice.
    Smith AJ, de Vree JM, Ottenhoff R, Oude Elferink RP, Schinkel AH, Borst P.
    Hepatology; 1998 Aug 01; 28(2):530-6. PubMed ID: 9696021
    [Abstract] [Full Text] [Related]

  • 15. Hepatic preneoplasia in hepatitis B virus transgenic mice.
    Toshkov I, Chisari FV, Bannasch P.
    Hepatology; 1994 Nov 01; 20(5):1162-72. PubMed ID: 7927248
    [Abstract] [Full Text] [Related]

  • 16. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice.
    Dunsford HA, Sell S, Chisari FV.
    Cancer Res; 1990 Jun 01; 50(11):3400-7. PubMed ID: 1692259
    [Abstract] [Full Text] [Related]

  • 17. Expression profile of nine novel genes differentially expressed in hepatitis B virus-associated hepatocellular carcinomas.
    Kim MY, Park E, Park JH, Park DH, Moon WS, Cho BH, Shin HS, Kim DG.
    Oncogene; 2001 Jul 27; 20(33):4568-75. PubMed ID: 11494152
    [Abstract] [Full Text] [Related]

  • 18. Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor II.
    Liu P, Terradillos O, Renard CA, Feldmann G, Buendia MA, Bernuau D.
    Hepatology; 1997 Apr 27; 25(4):874-83. PubMed ID: 9096591
    [Abstract] [Full Text] [Related]

  • 19. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
    Wirth S, Guidotti LG, Ando K, Schlicht HJ, Chisari FV.
    J Immunol; 1995 Mar 01; 154(5):2504-15. PubMed ID: 7868916
    [Abstract] [Full Text] [Related]

  • 20. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion.
    Etiemble J, Degott C, Renard CA, Fourel G, Shamoon B, Vitvitski-Trépo L, Hsu TY, Tiollais P, Babinet C, Buendia MA.
    Oncogene; 1994 Mar 01; 9(3):727-37. PubMed ID: 8108115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.